文献速递核素与放射性配体治疗

串联肽受体放射性核素治疗使用90Y/177Lu-DOTATATE对神经内分泌肿瘤的疗效与副作用——波兰多中心经验

Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-24

该多中心研究纳入103例G1/G2级播散性神经内分泌肿瘤患者,采用90Y/177Lu-DOTATATE(1:1)串联肽受体放射性核素治疗并输注氨基酸保护肾脏。结果显示中位总生存期自诊断起127.4个月、自治疗起89.5个月,无进展生存期29.9个月,G1级患者无进展生存期与总生存期均优于G2级,治疗耐受良好,仅1例发生骨髓增生异常综合征。

要点

  • 串联90Y/177Lu-DOTATATE治疗播散性NET的PFS为29.9个月,OS-T为89.5个月,OS-D为127.4个月。
  • G1级患者PFS 59.3个月 vs G2级24.3个月,OS-T G1级未达到 vs G2级79.9个月,差异有统计学意义。
  • 2年进展风险42%,2年和5年总生存概率分别为89%和62%,仅1例(1%)发生骨髓增生异常综合征。

核心结论

  • 该多中心试验表明串联90Y/177Lu-DOTATATE对播散性NET患者高效且安全。

研究设计与样本

  • 多中心试验,纳入103例接受90Y/177Lu-DOTATATE(1:1)串联PRRT并输注氨基酸保护肾脏的G1/G2级NET患者。

主要发现

  • 自疾病诊断起总生存期(OS-D)为127.4个月,自PRRT起总生存期(OS-T)为89.5个月,无进展生存期(PFS)为29.9个月。
  • 基于增殖指数的分析显示对PFS和OS-T有统计学显著影响:PFS G1级 vs G2级为59.3 vs 24.3个月;OS-T G1级未达到 vs G2级79.9个月。
  • 原发疾病部位分析:胰腺 vs 小肠 vs 大肠,PFS分别为30.8 vs 30.3 vs 40.6个月,OS-T分别为94 vs 61.9 vs 131.2个月,OS-D分别为130.4 vs 89.2 vs 未达到个月。
  • 2年进展风险为42%,2年和5年总生存概率分别为89%和62%。
  • 所有患者对PRRT耐受良好,1例(1%)发生骨髓增生异常综合征,未观察到其他3级和4级血液学或肾脏毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: One of the concepts of theranostics in nuclear medicine is peptide receptor radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging and treating inoperable or disseminated neuroendocrine tumors (NET). AIM: The aim of the study was to determine the therapeutic efficacy and toxicity of tandem 90Y /177Lu-DOTATATE in patients with disseminated NET in a multicenter trial. MATERIALS AND METHODS: 103 patients with NET G1/G2 treated with 90Y/177Lu-DOTATATE (1:1) with amino-acid infusion for nephroprotection were included in the study. RESULTS: Overall survival from the disease diagnosis (OS-D) was 127.4 months and from the time of PRRT (OS-T) was 89.5 months. Progression-free survival (PFS) was 29.9 months. An analysis based on the proliferation index revealed a statistically significant impact on PFS and OS-T (PFS G1 vs G2, 59.3 vs 24.3 months; OS-T G1 vs G2, not reached vs 79.9 months). The effect of the primary disease site was also analyzed. For pancreatic vs small bowel vs large bowel, the PFS was 30.8 vs 30.3 vs 40.6 months, the OS-T was 94 vs 61.9 vs 131.2 months and OS-D was 130.4 vs 89.2 vs not reached months, respectively. The 2-year risk of progression was 42%. The probability of 2-year and 5-year overall survival was 89% and 62%, respectively. PRRT was well tolerated by all patients. One patient (1%) developed myelodysplastic syndrome. No other grade 3 and 4 hematological or renal toxicity was observed. CONCLUSIONS: This multicenter trial showed that tandem 90Y/177Lu-DOTATATE is highly effective and safe therapy for patients with disseminated NET.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020. PMID: 31980909. doi:10.1007/s00259-020-04690-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。